We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment‐resistant schizophrenia in patients with 3q29 deletion: A case series of four patients.
- Authors
Nawa, Yoshihiro; Kushima, Itaru; Aleksic, Branko; Yamamoto, Maeri; Kimura, Hiroyuki; Banno, Masahiro; Hashimoto, Ryota; Ozaki, Norio
- Abstract
Another SCZ patient with 3q29 deletion was also reported to be treatment resistant.5 As D2 receptor antagonists were not effective, a hyperdopaminergic state in the mesolimbic dopamine pathways may not play a crucial role in 3q29 deletion-associated psychosis. The 3q29 deletion is one of the strongest risk factors (odds ratio > 40) for schizophrenia (SCZ)1 and is associated with other psychiatric disorders including intellectual disability (ID), autism spectrum disorder, and bipolar disorder.2 However, details of psychiatric manifestations and treatment responses have not been described in these patients. CPZ, chlorpromazine; EEG, electroencephalography; ID, intellectual disability; IQ, intelligence quotient; MRI, magnetic resonance imaging; N/A, not available; SCZ, schizophrenia. gl Patient 1, a 55-year-old female, was born with low birth weight. Treatment-resistant schizophrenia in patients with 3q29 deletion: A case series of four patients.
- Subjects
PEOPLE with schizophrenia; ANTI-NMDA receptor encephalitis; POSITRON emission tomography; COMPARATIVE genomic hybridization; HYPERACUSIS
- Publication
Psychiatry & Clinical Neurosciences, 2022, Vol 76, Issue 7, p338
- ISSN
1323-1316
- Publication type
Article
- DOI
10.1111/pcn.13361